10-K: Shell Company NIMS Faces Going Concern, Reports Wider Losses

Non-Invasive Monitoring Systems, Inc. (NIMS) reported increased net losses and a deteriorating financial position, raising substantial doubt about its ability to continue as a going concern.

Summary

• NIMS, a shell company since May 2019, reported a net loss of $222,000 for the fiscal year ended July 31, 2025, an increase from $113,000 in the prior year.
• The company's cash balance decreased significantly to $3,000 as of July 31, 2025, from $25,000 in the previous year.
• Negative working capital worsened to approximately $947,000 at July 31, 2025, compared to $725,000 at July 31, 2024.
• An accumulated deficit reached $29.0 million as of July 31, 2025.
• Total operating costs and expenses from continuing operations increased to $160,000 in 2025 from $59,000 in 2024, primarily due to a $118,000 accounts payable adjustment in the prior year that reduced expenses.
• The company continues to rely on related-party financing, with notes payable to Frost Gamma Investments Trust and Dr. Jane Hsiao totaling $595,000 as of July 31, 2025, up from $500,000 in 2024.
• NIMS experienced delays in filing its Annual Report on Form 10-K for FY2025 and a subsequent Quarterly Report on Form 10-Q, but expects to become current with the filing of this report.
• Management identified material weaknesses in internal controls over financial reporting, including insufficient segregation of duties and undocumented procedures, concluding that controls were not effective as of July 31, 2025.
• The Board of Directors, which functions as the audit and compensation committee, no longer includes any independent directors following a resignation in August 2025.

Sentiment

Score: 1

Explanation: StockSavvy.ai views this filing as highly negative due to the severe financial distress, explicit 'going concern' warning, increasing losses, critical internal control weaknesses, and lack of independent governance, indicating significant operational and financial instability.

Positives

• Net cash used in operating activities decreased to $117,000 for the year ended July 31, 2025, compared to $182,000 for the year ended July 31, 2024, indicating a reduced cash burn from operations.

Negatives

• Net loss increased to $222,000 for the year ended July 31, 2025, from $113,000 in the prior year.
• Cash on hand significantly decreased to $3,000 at July 31, 2025, from $25,000 at July 31, 2024.
• Negative working capital worsened to approximately $947,000 at July 31, 2025.
• The accumulated deficit grew to $29.0 million as of July 31, 2025.
• Total operating costs and expenses increased to $160,000 in 2025 from $59,000 in 2024, primarily due to a non-recurring accounts payable adjustment in 2024.
• Interest expense increased to $62,000 in 2025 from $54,000 in 2024.
• The company has a history of operating losses and does not expect to become profitable in the near future.
• Substantial doubt exists about the company's ability to continue as a going concern without additional equity or debt financing.
• Material weaknesses were identified in internal controls over financial reporting, indicating a risk of financial misstatements.
• The Board of Directors lacks independent members to serve on audit and compensation committees, creating potential conflicts of interest.

Risks

• A history of operating losses and no expectation of near-term profitability, with substantial doubt about the ability to continue as a going concern without additional financing.
• Requirement for additional funding, which may not be available on acceptable terms or at all, potentially leading to significant shareholder dilution or restrictive debt covenants.
• Past delays in filing SEC reports, with a risk of recurrence that could negatively impact investor confidence, information availability, and stock liquidity/price.
• Exposure to risks related to management's assessment of disclosure controls and procedures and internal controls over financial reporting, including identified material weaknesses.
• Lack of an audit or compensation committee made up of independent directors, requiring shareholders to rely on a board with only one (now zero) independent director to perform these crucial functions.
• No anticipation of paying dividends on common stock in the foreseeable future, meaning investors may only receive a return through stock price appreciation.
• The common stock is a 'penny stock,' making it more difficult for investors to sell shares and potentially adversely affecting the market price.
• Stock price volatility and the potential for an inactive, illiquid trading market for common stock.
• Fluctuations in quarterly results of operations, which could cause the stock price to decline.
• Potential dilution of ownership interests due to the future issuance of additional authorized common and preferred stock.

Future Outlook

The company expects to continue incurring operating losses and does not anticipate becoming profitable in the near future. It will require additional funding to continue as a going concern, primarily through equity offerings, debt financings, or mergers/acquisitions. There is no assurance that such funding will be available on acceptable terms or at all. The company is actively assessing potential mergers and acquisitions.

Management Comments

• Management has implemented measures intended to improve the timeliness of future SEC filings, including enhancements to internal reporting processes and increased oversight of the financial reporting function.
• Management believes that the consolidated financial statements included in this Form 10-K fairly present in all material respects the company's financial condition, results of operations, and cash flows for the periods presented, despite identified material weaknesses in internal control over financial reporting.

Industry Context

StockSavvy.ai notes that NIMS operates as a shell company, having discontinued its primary business operations in May 2019. This status places it outside typical industry comparisons, as its focus is solely on identifying a suitable merger or acquisition candidate rather than generating revenue from products or services. The reliance on related-party financing and the persistent 'going concern' warning are common characteristics of dormant or shell entities seeking a transformative event, highlighting the speculative nature of investment in such companies.

Comparison to Industry Standards

• As a shell company with no active operations or revenue, NIMS does not meet the operational or financial benchmarks of a typical publicly traded company in any specific industry.
• Its financial metrics, including recurring net losses, minimal cash reserves ($3,000), and significant accumulated deficit ($29.0 million), are indicative of a company in severe financial distress, far below the liquidity and profitability standards of even early-stage operational biotech or medical device companies.
• The reliance on related-party debt for continued existence, with $595,000 in notes payable to its Chairman/CEO and a controlling trust, is a common characteristic of distressed companies or shell entities, but it also highlights a lack of access to conventional financing that operating companies typically secure.
• The identified material weaknesses in internal controls and the absence of independent directors on key committees fall short of corporate governance best practices expected of publicly traded entities, regardless of size or operational status, and are a red flag compared to well-governed companies like Johnson & Johnson or Medtronic in the broader healthcare sector.

Management Changes

Corporate Governance

Related Party Transactions

• The principal corporate office is leased at $0 per month from Frost Real Estate Holdings, LLC, a company controlled by Dr. Phillip Frost, a director and significant beneficial shareholder.
• Accounts payable at July 31, 2025, include $13,100 due to an officer and director of the company.
• The company has outstanding promissory notes totaling $445,000 as of July 31, 2025, to Frost Gamma Investments Trust, a trust controlled by Dr. Phillip Frost. These notes accrue interest at 11% per annum and have a maturity date of June 30, 2026 (as amended).
• The company has outstanding promissory notes totaling $150,000 as of July 31, 2025, to Dr. Jane Hsiao, the company's Chairman and Interim CEO. These notes accrue interest at 11% per annum and have a maturity date of June 30, 2026 (as amended).
• Subsequent to July 31, 2025, additional promissory notes totaling $125,000 were entered into with Frost Gamma Investments Trust, accruing interest at 11% per annum and maturing on June 30, 2026.
• OPKO Health, Inc., a related party under common control (Dr. Phillip Frost is CEO/Chairman of OPKO), holds a one percent ownership interest in NIMS and accounts for it as an equity method investment.

Stakeholder Impact

• Shareholders face significant risk of dilution from future capital raises and potential loss of investment due to the 'going concern' uncertainty.
• Shareholders are impacted by the illiquidity and volatility of the common stock, which trades as a penny stock.
• The lack of independent directors and material weaknesses in internal controls raise concerns about the protection of shareholder interests and the reliability of financial reporting.
• Creditors, particularly related parties, are exposed to the risk of non-payment given the company's severe financial distress and reliance on continued financing.

Next Steps

• Assess potential mergers and acquisitions.
• Raise additional capital through public or private equity offerings, debt financings, or strategic collaborations.
• Remediate identified material weaknesses in internal controls over financial reporting.
• Improve the timeliness of future SEC filings.

Key Dates

Recommendation

The filing presents a dire financial situation for NIMS, a shell company with no active operations, increasing net losses, critically low cash reserves ($3,000), and a substantial accumulated deficit ($29.0 million). The explicit 'going concern' warning, coupled with identified material weaknesses in internal controls and a complete lack of independent directors on its board and committees, signals profound operational and governance risks. While the company is seeking M&A opportunities, its current state offers no intrinsic value or clear path to recovery. The reliance on related-party financing, while keeping it afloat, does not address the fundamental issues. For a seasoned investor, these factors collectively indicate an extremely high-risk investment with a high probability of further value erosion, making a 'strong sell' recommendation appropriate.

Keywords

shell company, going concern, net loss, negative working capital, related party debt, SEC filing delays, internal control weaknesses, corporate governance, penny stock, merger and acquisition search